LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy

This study has been completed.

First Received: May 19, 2006 Last Updated: December 26, 2007 History of Changes

Sponsored by:	Astellas Pharma Inc
Information provided by:	Astellas Pharma Inc
ClinicalTrials.gov Identifier:	NCT00328588

Purpose

A study for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients previously treated with chemotherapy.

Condition	Intervention	Phase
Lung Cancer Cancer of Lung Cancer of the Lung Non-Small Cell Lung Carcinoma Carcinoma, Non-Small Cell Lung	Drug: YM155	Phase II

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:

Tumor response rate (CR+PR) [ Time Frame: In first 6 cycles ] [ Designated as safety issue: No ]

Enrollment:	37
Study Start Date:	December 2006
Study Completion Date:	March 2007
Primary Completion Date:	March 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental 7 days continuous infusion	Drug: YM155 IV

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00328588

Locations

Sponsors and Collaborators

Astellas Pharma Inc

Investigators

Study Director:

Medical Director

Astellas Pharma Europe BV

More Information

No publications provided

Responsible Party:	Astellas Pharma Europe BV ( Disclosure Office Europe )
Study ID Numbers:	155-CL-006
Study First Received:	May 19, 2006
Last Updated:	December 26, 2007
ClinicalTrials.gov Identifier:	NCT00328588 History of Changes
Health Authority:	United Kingdom: Medicines and Healthcare Products Regulatory Agency; Netherlands: Medicines Evaluation Board (MEB); Czech Republic: State Institute for Drug Control; Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Astellas Pharma Inc:

Treatment Efficacy
Treatment Effectiveness
Disease Management
Treatment
Safety

Study placed in the following topic categories:

Thoracic Neoplasms
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases

Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:

Thoracic Neoplasms
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type
Respiratory Tract Diseases

Lung Neoplasms
Lung Diseases
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

ClinicalTrials.gov processed this record on September 11, 2009